ArticleFrontiers in endocrinology2025
Apigenin promotes remodeling of peripheral and skeletal adipocytes in response to β3-AR and TLR4 activation.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation impairs adipocyte browning and diminishes the protective role of adaptive thermogenesis against obesity and metabolic disorders. The aim of this study is to evaluate the effects of the anti-inflammatory dietary compound apigenin (Api) on adaptive thermogenesis in C57BL/6 mice in the presence of inflammation and to determine whether changes occur in skeletal adipocytes in these mice. Methods: Lipopolysaccharide (LPS) was administered intraperitoneally at 8 µg/mouse every other day for 2 weeks to activate TLR4 signaling. Api was administered intraperitoneally at 30 mg/kg every other day for 2 weeks. To stimulate thermogenesis, CL316,243 (CL), a β3-adrenergic receptor agonist, was administered at 1 mg/kg during the final 5 days. Accordingly, four experimental groups were created: control, CL, LPS+CL, and Api+LPS+CL. Results: Our results show that Api restored CL-induced thermogenesis in LPS-injected mice. This effect was mediated by inguinal white adipose tissue (iWAT) browning, accompanied by reduced inflammation and alterations in genes involved in fatty acid oxidation and Conclusions: Collectively, Api positively regulates thermogenesis and lipid metabolism in iWAT of LPS-injected mice and promotes lipid accumulation in the bone marrow without causing perturbations in bone parameters. Therefore, Api holds promise for restoring thermogenesis under inflammatory conditions. However, further investigation is needed to elucidate the impact of Api-induced adipose tissue remodeling on skeletal health, particularly under conditions of prolonged supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.